<DOC>
	<DOC>NCT01497834</DOC>
	<brief_summary>The purpose of this study is to assess the anti-viral activity of BMS-790052 and BMS-650032 combination therapy in Japanese subjects.</brief_summary>
	<brief_title>A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Chronic HCV1b infected patient HCV RNA viral load of â‰¥ 100,000 IU/mL at screening Ages 20 to 75 years Nonresponder to Interferon plus Ribavirin therapy Patient who has been excluded from interferon/ribavirin therapy or intolerant for Interferon/Ribavirin therapy Patients who have Hepatocellular carcinoma Coinfection with Hepatitis B virus (HBV) or Human Immunodeficiency Virus (HIV) Severe or uncontrollable complication</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Hepatitis C Virus Infection</keyword>
</DOC>